Wikipedia
Melflufen
Melflufen (melphalan flufenamide hydrochloride, previously designated J1) is an anticancer drug under development by Oncopeptides AB. It is a peptidase activated derivative of melphalan, that exerts a targeted delivery to cells with high expression of aminopeptidases, such as Aminopeptidase N, which has been described as over expressed in human malignancies. Aminopeptidase N plays a functional role in malignant angiogenesis. Currently, melflufen is under evaluation in a multinational study for the treatment of patients with relapsed and refractory multiple myeloma.